Market Cap | 4.14M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -13.39M | Forward P/E | -0.31 | EPS next Y | - | 50D Avg Chg | -5.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -60.00% |
Dividend | N/A | Price/Book | 4.38 | EPS next 5Y | - | 52W High Chg | -89.00% |
Recommedations | - | Quick Ratio | 1.65 | Shares Outstanding | 45.04M | 52W Low Chg | 77.00% |
Insider Own | 9.77% | ROA | -52.00% | Shares Float | 35.32M | Beta | 2.10 |
Inst Own | 9.36% | ROE | -291.89% | Shares Shorted/Prior | 294.31K/427.54K | Price | 0.09 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 57,006 | Target Price | - |
Oper. Margin | - | Earnings Date | Nov 10 | Volume | 4,048 | Change | 0.00% |
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Piper Sandler | Overweight | Sep 30, 20 |
H.C. Wainwright | Buy | May 23, 18 |
Jefferies | Hold | Jan 6, 16 |
FBR Capital | Outperform | Apr 21, 15 |
Oppenheimer | Outperform | Apr 17, 15 |
Aegis Capital | Buy | Jan 23, 14 |
Rodman & Renshaw | Market Outperform | Sep 10, 12 |